A Dark Vector Cognition product

Item 16. Form 10-K Summary

3K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

None.

​

​

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bolingbrook, State of Illinois, on March 25, 2022.

​​​
​ULTA BEAUTY, INC.
​​​
​By:/s/ Scott M. Settersten
​​Scott M. Settersten
​​Chief Financial Officer, Treasurer and Assistant Secretary

​

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

​​​​​
SignaturesTitleDate
​​​​​
/s/ David C. Kimbell​Chief Executive Officer and​March 25, 2022
David C. Kimbell​Director (Principal Executive Officer)​​
​​​​​
/s/ Scott M. Settersten​Chief Financial Officer, Treasurer​March 25, 2022
Scott M. Settersten​and Assistant Secretary (Principal Financial and Accounting Officer)​​
​​​​​
/s/ Sally E. Blount​Director​March 25, 2022
Sally E. Blount​​​​
​​​​​
/s/ Michelle L. Collins​Director​March 25, 2022
Michelle L. Collins​​​​
​​​​​
/s/ Mary N. Dillon​Executive Chair of the Board of Directors​March 25, 2022
Mary N. Dillon​​​​
​​​​​
/s/ Kelly E. Garcia​Director​March 25, 2022
Kelly E. Garcia​​​​
​​​​​
/s/ Catherine Halligan​Director​March 25, 2022
Catherine Halligan​​​​
​​​​​
/s/ Charles Heilbronn​Director​March 25, 2022
Charles Heilbronn​​​​
​​​​​
/s/ Patricia A. Little​Director​March 25, 2022
Patricia A. Little​​​​
​​​​​
/s/ Michael R. MacDonald​Director​March 25, 2022
Michael R. MacDonald​​​​
​​​​​
/s/ George Mrkonic​Director​March 25, 2022
George Mrkonic​​​​
​​​​​
/s/ Lorna E. Nagler​Lead Independent Director of the Board of Directors​March 25, 2022
Lorna E. Nagler​​​​
​​​​​
/s/ Gisel Ruiz​Director​March 25, 2022
Gisel Ruiz​​​​
​​​​​
/s/ Michael C. Smith​Director​March 25, 2022
Michael C. Smith​​​​

​

​

Previous: Item 15. Exhibits and Financial Statement Schedules